A scientific leap for a rare disease
For children with rare diseases, a single breakthrough can change everything. In partnership with UConn Health, researchers at Connecticut Children’s helped bring forward the first FDA-approved gene therapy for glycogen storage disease type 1a (GSD1a) — a rare genetic disorder that keeps the liver from releasing glucose into the bloodstream. Without constant management, patients with GSD1a, like 6-year-old Lila, face life-threatening blood sugar levels that can lead to seizures or worse. Lila manages her disease by ingesting raw corn starch every few hours to maintain her blood sugar. But soon, a new treatment will be available to her. As one of the world’s leading institutions studying the disease, Connecticut Children’s served as a clinical trial site for a new therapy and administered the very first infusions worldwide. The one-time treatment delivers a working copy of the missing gene, helping patients maintain stable blood sugar with far less reliance on the around-the-clock doses of cornstarch that have defined life with GSD1a for decades. Thanks to advancements like this, more kids can maintain stronger blood sugar levels, living longer, more independent lives.